ExodusPoint Capital Management LP lessened its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 44.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 105,668 shares of the biotechnology company's stock after selling 83,431 shares during the quarter. ExodusPoint Capital Management LP owned about 0.21% of REGENXBIO worth $817,000 as of its most recent filing with the SEC.
Other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. grew its holdings in REGENXBIO by 67.0% during the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock valued at $31,975,000 after purchasing an additional 1,659,206 shares during the last quarter. Geode Capital Management LLC raised its holdings in REGENXBIO by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company's stock worth $8,460,000 after acquiring an additional 5,574 shares during the period. Assenagon Asset Management S.A. boosted its holdings in REGENXBIO by 53.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after acquiring an additional 296,700 shares during the period. Norges Bank acquired a new position in shares of REGENXBIO during the 4th quarter worth about $3,474,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in REGENXBIO by 9.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company's stock valued at $4,382,000 after purchasing an additional 37,055 shares during the period. 88.08% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on the stock. StockNews.com raised shares of REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, March 7th. Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research report on Tuesday, March 18th. Raymond James assumed coverage on shares of REGENXBIO in a research note on Friday, February 7th. They set an "outperform" rating and a $27.00 price target for the company. The Goldman Sachs Group lowered REGENXBIO from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $38.00 to $14.00 in a research note on Tuesday, February 11th. Finally, Chardan Capital reiterated a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a research report on Thursday, March 20th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $31.88.
Get Our Latest Analysis on REGENXBIO
REGENXBIO Stock Down 5.0 %
NASDAQ:RGNX traded down $0.33 during trading hours on Wednesday, hitting $6.22. 120,537 shares of the stock were exchanged, compared to its average volume of 795,460. REGENXBIO Inc. has a twelve month low of $5.04 and a twelve month high of $18.24. The company has a market capitalization of $311.73 million, a P/E ratio of -1.24 and a beta of 1.26. The company's 50 day moving average is $6.92 and its two-hundred day moving average is $8.23.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $21.21 million during the quarter, compared to analysts' expectations of $23.70 million. On average, equities research analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current year.
About REGENXBIO
(
Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Featured Articles
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
